Physician profile

Ivan Marlow Turpin

Plastic and Reconstructive Surgery · Orange, CA

NPI 1407815996

$1,879.26

in general payments reported to CMS, 2019-2025

7 companies · $145 in 2025

The $145 reported for 2025 was less than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).

See the full distribution for Plastic and Reconstructive Surgery

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$219.77

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Allergan, INC. $1,083.69 2019-2023
Merz North America, INC. $277.74 2022
Sientra, INC. $230.37 2019-2021
Abbvie INC. $144.57 2025
Ethicon US, LLC $71.85 2019-2020
Mentor Worldwide LLC $68.63 2019-2020
Apyx Medical Corporation $2.41 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Ivan Marlow Turpin

$1,879.26

in general payments reported 2019-2025

Years
2019-2025
Top company
Allergan, INC.
Context
The $145 reported for 2025 was less than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).

https://glasscript.com/doctor/289883/ivan-marlow-turpin

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.